Sun Pharmaceutical Industries Limited has introduced STARIZO (Tedizolid Phosphate) to the Indian market, a novel antibacterial treatment targeting Acute Bacterial Skin and Skin Structure Infections (ABSSSI), particularly those caused by drug-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA). This launch represents a significant advancement in addressing the growing concern of antibiotic-resistant infections in India. Skin […]
Sun Pharmaceutical Industries Limited unveiled data from its Phase 1 study of GL0034 (Utreglutide), targeting obesity in adults. The findings, presented at the 84th American Diabetes Association Scientific Sessions in Orlando, Florida, underscore significant weight loss and improved metabolic parameters among participants. The Phase 1, multiple ascending-dose study aimed to assess the safety, tolerability, pharmacokinetics, […]
Sun Pharma and Moebius Medical Limited, an Israel-based company, showcased compelling data at the European League Against Rheumatism (EULAR) 2024 conference. The results demonstrated the prolonged efficacy of the MM-II injection in providing pain relief for knee osteoarthritis (OA) patients up to 26 weeks post-injection. This data was derived from a phase 2b randomized controlled […]
In a significant development for the Indian healthcare sector, Sun Pharmaceutical Industries Limited and Bayer have announced a collaborative agreement to market and distribute a second brand of Finerenone in India. This move is set to revolutionize the treatment landscape for chronic kidney disease (CKD) associated with type 2 diabetes mellitus (T2DM). Finerenone: A Game-Changer […]
Sun Pharmaceutical Industries Limited has entered into a license agreement with U.S.-based biopharmaceutical company Pharmazz Inc. for the commercialization of the first-in-class innovative drug, Tyvalzi (Sovateltide), in India. The deal terms include undisclosed upfront and milestone payments, as well as royalties to Pharmazz. Sovateltide is indicated for treating cerebral ischemic stroke and has recently been […]
Sun Pharmaceutical Industries has unveiled positive results from two Phase 1 studies assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of GL0034, a novel long-acting GLP-1 receptor agonist, in non-obese and obese adults without diabetes. The findings will be presented in poster sessions at the American Diabetes Association’s 83rd Scientific Sessions in San Diego. One of […]
Sun Pharma Canada, a subsidiary of Sun Pharmaceutical Industries, has secured Health Canada’s approval for their pioneering acne treatment, WINLEVI (clascoterone cream 1%). This marks the first approval of an androgen receptor inhibitor for topical treatment of acne vulgaris in patients aged 12 and older, presenting a groundbreaking advancement in acne treatments for Canadian patients […]
MMP Industries, a Nagpur-based manufacturer of aluminum powders, aluminum foils, and aluminum conductors, has bagged its first commercial order from Sun Pharmaceutical Industries for the packaging of the pharma company’s products. According to MMP Industries, it had previously won an identical order from another major pharma company. MMP Industries said that through this order from […]
India-based Sun Pharmaceutical Industries (Sun Pharma) will acquire US-based Concert Pharmaceuticals for equity consideration of $576 million to strengthen its global dermatology franchise. Concert Pharmaceuticals is developing deuruxolitinib, a novel, deuterated, oral Janus kinases JAK1/2 inhibitor for the treatment of Alopecia Areata, an autoimmune dermatological disease resulting in partial or complete loss of hair on […]
Sun Pharmaceutical Industries (Sun Pharma) said that one of its fully-owned subsidiaries has launched the generic version of Pfizer-developed Palbociclib in India for patients with advanced breast cancer. The Indian pharma company will make the anti-cancer drug available under the brand name PALENO (Palbociclib) 75 mg, 100 mg, and 125 mg. Palbociclib has approval in […]
